ReviewBritish journal of clinical pharmacology2008
Adalimumab in dermatology.
Review in British journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 49 citations in OpenAlex.
- Glial Cell Dynamics in Neuroinflammation: Mechanisms, Interactions, and Therapeutic Implications.Biomedicines · 2026Review
- Effects of Immunomodulatory Therapy on the Skin Barrier Function in Patients with Psoriasis Vulgaris.Medicina (Kaunas, Lithuania) · 2025Article
- Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders.Current issues in molecular biology · 2025Review
- Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic Frontiers.Biomedicines · 2025Review
- Smartphone-assisted portable immunosensor toward on-site detection of tumor necrosis factor-α inhibitor adalimumab for personalized treatment.Mikrochimica acta · 2025Article
- Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction.Frontiers in cellular and infection microbiology · 2025Review
- Successful Treatment of Annular Atrophic Lichen Planus With Adalimumab.Clinical case reports · 2025Article
- Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.International journal of molecular sciences · 2022Review
- Recalcitrant Dissecting Cellulitis of the Scalp Treated Successfully with Adalimumab with Hair Regrowth: A Case Report.Clinical, cosmetic and investigational dermatology · 2021Article
- Article
- Review
- Extensive phlegmon and pyoderma gangrenosum: diagnostic difficulties.Postepy dermatologii i alergologii · 2015Article
- Multicentric reticulohistiocytosis: a rare yet challenging disease.Clinical reviews in allergy & immunology · 2013Review
- Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.British journal of pharmacology · 2010Review
- Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Clinical, cosmetic and investigational dermatology · 2010Article
- Development of pyoderma gangrenosum during therapy with infliximab.Journal of dermatological case reports · 2009Article
- Looking back: editors' pick of 2008.British journal of clinical pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adalimumab is a biological agent, one of the tumour necrosis factor-alpha inhibitors. Pivotal studies evaluating its efficacy in plaque psoriasis (CHAMPION, REVEAL) and psoriatic arthritis (PsA) (ADEPT) were carried out in recent years. Adalimumab proved highly effective in psoriasis patients and in PsA patients previously unresponsive to nonsteroidal anti-inflammatory drugs. Results of smaller studies suggest therapy with the drug may be successful in psoriasis resistant to other biologics and PsA unresponsive to disease-modifying antirheumatic drugs. Adalimumab has also been shown to improve patients' quality of life significantly. Although they should be further extended as far as dermatological conditions are concerned, available data indicate adalimumab is safe and well tolerated. Numerous case reports featuring its off-label use suggest the drug could be helpful in treating hidradenitis suppurativa, pyoderma gangrenosum, Sweet's syndrome, cutaneous sarcoidosis, pemphigus, systemic vasculitides, multicentric reticulohistiocytosis and stomatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.